Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Intellia Therapeutics's Nexiguran Ziclumeran?
Nexiguran Ziclumeran is a gene therapy commercialized by Intellia Therapeutics, with a leading Phase III program in Familial Amyloid Cardiomyopathy....